Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndrome
Key claim: The FDA is classifying the external lower extremity nerve stimulator for Restless Legs Syndrome as a Class II medical device subject to special controls to provide reasonable assurance of safety and effectiveness while enhancing patient access.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the external lower extremity nerve stimulator for Restless Legs Syndrome into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the external lower extremity nerve stimulator for Restless Legs Syndrome. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Class II classification with special controls establishes a defined regulatory pathway for external lower extremity nerve stimulators used to treat Restless Legs Syndrome, which can lower barriers for manufacturers seeking 510(k) clearance and expand patient access to a non-pharmacologic option. For patients and providers, this may translate over time into broader availability of FDA-cleared RLS devices, though coverage and out-of-pocket costs depend on separate payer decisions.